BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33503448)

  • 1. LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation.
    Chen L; Wang YY; Li D; Wang C; Wang SY; Shao SH; Zhu ZY; Zhao J; Zhang Y; Ruan Y; Han BM; Xia SJ; Jiang CY; Zhao FJ
    Cancer Lett; 2021 Apr; 503():138-150. PubMed ID: 33503448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LIM domain only 2 over-expression in prostate stromal cells facilitates prostate cancer progression through paracrine of Interleukin-11.
    Jiang CY; Yu JJ; Ruan Y; Wang XH; Zhao W; Wang XJ; Zhu YP; Gao Y; Hao KY; Chen L; Han BM; Xia SJ; Zhao FJ
    Oncotarget; 2016 May; 7(18):26247-58. PubMed ID: 27028859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
    Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
    Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.
    Cioni B; Nevedomskaya E; Melis MHM; van Burgsteden J; Stelloo S; Hodel E; Spinozzi D; de Jong J; van der Poel H; de Boer JP; Wessels LFA; Zwart W; Bergman AM
    Mol Oncol; 2018 Aug; 12(8):1308-1323. PubMed ID: 29808619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
    Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.
    Kregel S; Szmulewitz RZ; Vander Griend DJ
    Prostate; 2014 Nov; 74(15):1530-43. PubMed ID: 25175748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal factors involved in human prostate cancer development, progression and castration resistance.
    Eiro N; Fernandez-Gomez J; Sacristán R; Fernandez-Garcia B; Lobo B; Gonzalez-Suarez J; Quintas A; Escaf S; Vizoso FJ
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):351-359. PubMed ID: 27787597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bidirectional Cross-talk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer.
    Wei J; Yin L; Li J; Wang J; Pu T; Duan P; Lin TP; Gao AC; Wu BJ
    Cancer Res; 2021 Aug; 81(16):4275-4289. PubMed ID: 34167949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.
    Chang MA; Patel V; Gwede M; Morgado M; Tomasevich K; Fong EL; Farach-Carson MC; Delk NA
    J Cell Biochem; 2014 Dec; 115(12):2188-97. PubMed ID: 25103771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
    Verma S; Shankar E; Chan ER; Gupta S
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.
    Liao CP; Chen LY; Luethy A; Kim Y; Kani K; MacLeod AR; Gross ME
    Endocr Relat Cancer; 2017 Apr; 24(4):157-170. PubMed ID: 28264911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
    Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
    Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.
    Chan SC; Selth LA; Li Y; Nyquist MD; Miao L; Bradner JE; Raj GV; Tilley WD; Dehm SM
    Nucleic Acids Res; 2015 Jul; 43(12):5880-97. PubMed ID: 25908785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.